TrialThe oncologist2021

A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy.

Fei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.